Jeff Behrens is CEO and co-founder of LabShares Newton, a biotech incubator for biotech startups run by biotech entrepreneurs. He is the former president and CEO of Siamab Therapeutics, a biotech company focused on developing antibodies targeting glycan targets in cancer. Previously, Jeff served as senior director of business development and operations at Edimer Pharmaceuticals (funded by Third Rock Ventures), and also worked at Alnylam Pharmaceuticals and Biogen Idec, where he co-founded Biogen’s Innovation Incubator.
In 2003, Jeff sold his health care IT company, The Telluride Group, to mindSHIFT Technologies, a Fidelity-funded rollup.
Jeff has an M.S. from the Harvard-MIT Program in Health Sciences and Technology, an M.B.A. from the MIT Sloan School of Management, and an A.B. from Harvard College